Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis.

Autor: Rivolta F; Department of Internal Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy., Sangalli A; Allergy and Clinical Immunology Residency University of Milan Milan Italy., Cappelletti C; Allergy and Clinical Immunology Residency University of Milan Milan Italy., Chiei Gallo A; Allergy and Clinical Immunology Residency University of Milan Milan Italy., Dubini M; Allergy and Clinical Immunology Residency University of Milan Milan Italy., Pravettoni V; Department of Internal Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2023 Mar 24; Vol. 11 (3), pp. e7067. Date of Electronic Publication: 2023 Mar 24 (Print Publication: 2023).
DOI: 10.1002/ccr3.7067
Abstrakt: A graded challenge with adalimumab could be safe in case of a delayed allergic reaction to golimumab, after a detailed allergological evaluation and the exclusion of allergic sensitization using skin tests.
Competing Interests: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.
(© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje